A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Brief description of study

The purpose of this study is to test the effectiveness and safety of standard chemotherapy drug along with carboplatin, compared to the standard chemotherapy drug without carboplatin. Patients will receive doxorubicin/cyclophosphamide followed by paclitaxel. Carboplatin is FDA-approved for the treatment of cancer and is used for the treatment of breast cancer that has spread. FDA is the U.S Food and Drug Administration, the health authority that gives approval for new medicines to be prescribed in the United States.


Clinical Study Identifier: s18-01785
ClinicalTrials.gov Identifier: NCT02488967
Principal Investigator: Nina D'Abreo.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.